Biocept Stock

Biocept Cash Conversion Cycle

Delisted

The Cash Conversion Cycle (CCC) of Biocept (BIOC) as of Sep 6, 2026 is 20.53. In the previous year, Cash Conversion Cycle (CCC) was 37.74 — a change of -45.60% (lower).

Cash Conversion Cycle

20.53

YoY

-45.60%

Last updated:

Cash Conversion Cycle (CCC) of Biocept is 2026 20.53 . Cash Conversion Cycle (CCC) of Biocept was 2025 37.74 . It decreases by -45.60% lower compared to the previous year.

The Biocept Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2015
-4.54 USD
Jan 1, 2016
-6.98 USD
Jan 1, 2017
55.57 USD
Jan 1, 2018
123.56 USD
Jan 1, 2019
191.70 USD
Jan 1, 2020
77.86 USD
Jan 1, 2021
37.74 USD
Jan 1, 2022
20.53 USD
The Biocept Cash Conversion Cycle history
YEARCash Conversion CycleYoY
20.53-45.60%
37.74-51.52%
77.86-59.39%
191.70+55.14%
123.56+122.36%
55.57-896.19%
-6.98+53.67%
-4.54-90.69%
-48.76
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Cash Conversion Cycle (CCC) of Biocept is 20.53 in 2026.

Cash Conversion Cycle (CCC) of Biocept changed from 37.74 to 20.53, representing a -45.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Biocept since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Biocept

All Key Metrics — Biocept